SK Biopharmaceuticals Co., Ltd. (KRX: 326030)
South Korea flag South Korea · Delayed Price · Currency is KRW
102,100
-1,500 (-1.45%)
Dec 20, 2024, 3:30 PM KST

SK Biopharmaceuticals Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Net Income
57,383-32,883-139,43164,846-247,414-71,519
Upgrade
Depreciation & Amortization
17,45915,31712,98411,64210,8596,501
Upgrade
Loss (Gain) From Sale of Assets
-162.2821.1111.283.020.292,007
Upgrade
Asset Writedown & Restructuring Costs
3,1686,808172.96---
Upgrade
Loss (Gain) From Sale of Investments
-1,282-12,2432,858-2,208-1,987-
Upgrade
Loss (Gain) on Equity Investments
27,08811,53514,92734,544--
Upgrade
Stock-Based Compensation
8,0753,23360.66416.71--
Upgrade
Other Operating Activities
-17,013-10,34714,161-132,4027,091-11,445
Upgrade
Change in Accounts Receivable
-56,012-52,456-13,169-41,610-9,050-189.43
Upgrade
Change in Inventory
-6,781-13,708-38,693-29,459-16,630-6,733
Upgrade
Change in Accounts Payable
1,111-20,7116,965607.698,961-
Upgrade
Change in Other Net Operating Assets
-13,29411,232-20,767748.3837,44344.38
Upgrade
Operating Cash Flow
19,738-94,201-159,920-92,872-210,726-81,335
Upgrade
Capital Expenditures
-1,034-2,385-4,911-4,316-11,023-13,200
Upgrade
Sale of Property, Plant & Equipment
---11.24-2,970
Upgrade
Cash Acquisitions
-31,043----
Upgrade
Sale (Purchase) of Intangibles
-11,382-864.17-1,050-1,676-3,314-627.5
Upgrade
Investment in Securities
4,235198,587-89,691265,618-303,722-28,541
Upgrade
Other Investing Activities
-2,768-1,104-10.78-639.56-714.24-68.67
Upgrade
Investing Cash Flow
-10,979225,273-95,714258,971-318,730-39,465
Upgrade
Short-Term Debt Issued
----150,000100,000
Upgrade
Long-Term Debt Issued
--141,751---
Upgrade
Total Debt Issued
100,000-141,751-150,000100,000
Upgrade
Short-Term Debt Repaid
-----250,000-
Upgrade
Long-Term Debt Repaid
--5,575-5,477-4,827-4,562-2,759
Upgrade
Total Debt Repaid
-104,884-5,575-5,477-4,827-254,562-2,759
Upgrade
Net Debt Issued (Repaid)
-4,884-5,575136,274-4,827-104,56297,241
Upgrade
Issuance of Common Stock
----645,465-
Upgrade
Other Financing Activities
-8,37212,198-1,360180.69--
Upgrade
Financing Cash Flow
-13,2566,623134,914-4,646540,90297,241
Upgrade
Foreign Exchange Rate Adjustments
-864.51-2,054-1,1435,135-3,254408.33
Upgrade
Miscellaneous Cash Flow Adjustments
-0--0--
Upgrade
Net Cash Flow
-5,361135,640-121,863166,5898,192-23,151
Upgrade
Free Cash Flow
18,705-96,586-164,831-97,188-221,749-94,534
Upgrade
Free Cash Flow Margin
3.66%-27.22%-66.96%-23.21%-852.91%-76.33%
Upgrade
Free Cash Flow Per Share
238.84-1233.33-2104.77-1241.01-3089.90-1454.38
Upgrade
Cash Interest Paid
9,5288,1423,488844.194,4411,234
Upgrade
Cash Income Tax Paid
12,6048,1264,6816,1606,389707.68
Upgrade
Levered Free Cash Flow
-25,324-54,562-108,21051,274-163,014-57,633
Upgrade
Unlevered Free Cash Flow
-18,807-49,387-105,88851,865-160,225-56,666
Upgrade
Change in Net Working Capital
67,89238,00430,98713,1337,060-197.21
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.